Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed
Using the Multiple Sclerosis Impact Scale to Estimate Health State Utility Values: Mapping from the MSIS-29, Version 2, to the EQ-5D and the SF-6D.
Neuroimaging of Natalizumab Complications in Multiple Sclerosis: PML and Other Associated Entities.
Melanoma complicating treatment with natalizumab for multiple sclerosis.
A Clinical Study Using MEDI-551 in Adult Subjects With Relapsed or Refractory Advanced B-Cell Malignancies
Where Do AQP4 Antibodies Fit in the Pathogenesis of NMO?
Reduced R2' in multiple sclerosis normal appearing white matter and lesions may reflect decreased myelin and iron content.
Anti-inflammatory effects of levetiracetam in experimental autoimmune encephalomyelitis.
Perforin Expression by CD4+ Regulatory T Cells Increases at Multiple Sclerosis Relapse: Sex Differences.
Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis.
[CHANGES IN THE QUALITATIVE AND QUANTITATIVE COMPOSITION OF GUT MICROBIOTA IN RATS DURING EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS].
Purinergic receptor P2RY12-dependent microglial closure of the injured blood-brain barrier.
Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis Patients.
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial.
The invisible gorilla strikes again: sustained inattentional blindness in expert observers.
Neuroprotection With Phenytoin in Optic Neuritis
Personality traits of patients with multiple sclerosis and their relationship with clinical characteristics.
Increased oligodendrogenesis by humanin promotes axonal remyelination and neurological recovery in hypoxic/ischemic brains.
The treatment of spasticity with Delta9-tetrahydrocannabinol in persons with spinal cord injury.
Tumor necrosis factor beta (TNF-β) NcoI polymorphism is associated with multiple sclerosis in Caucasian patients from Southern Brazil independently from HLA-DRB1.
Orally Active 7-Substituted (4-Benzyl-phthalazin-1-yl)-2-methyl-piperazin-1-yl]-nicotinonitriles as Active-site Inhibitors of Sphingosine-1-Phosphate Lyase for the Treatment of Multiple Sclerosis.
OnabotulinumtoxinA (Botox(®)): A Review of its Use in the Treatment of Urinary Incontinence in Patients with Multiple Sclerosis or Subcervical Spinal Cord Injury.
[Transorbital echography for assessment of optical nerve atrophy in demyelinating diseases: a pilot study].
Epstein-Barr virus cause of multiple sclerosis.
CAR/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery.
Cross-Immunoreactivity between Bacterial Aquaporin-Z and Human Aquaporin-4: Potential Relevance to Neuromyelitis Optica.
Pages
« first
‹ previous
…
228
229
230
231
232
233
234
235
236
…
next ›
last »